Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 25, 2026
ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how payment reliability has become a competitive differentiator at high-performing sites, what a truly strategic lean development model looks like, and a licensing deal for a next-generation obesity therapy combining Phase I data with preclinical validation.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part one of a new interview , Patrick Mizer, chief technology officer at Ledger Run, explains how the shift from competing for patients to competing for high-performing sites has made payment reliability an operational brand. Sites now prioritize which trials to join based on sponsor track records for timely payments and financial predictability, a factor materially influencing enrollment and site quality. - In a
new Q&A , Stella K. Vnook, PhD, CEO and executive chair of Kaida BioPharma and founder and CEO of Aviva Ventures, discussed how declining NIH funding, late-stage pharma acquisition focus, and global trial speed are forcing early-stage biotechs to move faster and deploy capital more strategically on inflection point data. Commercialization input must now inform clinical decisions at indication selection and trial design rather than after Phase II, a shift that demands fundamentally different planning disciplines. Hanmi Pharm licensed HM17321 to Genentech for development, regulatory, and commercial milestones totaling up to $2.3 billion , with a $190 million upfront payment and tiered royalties on future sales. HM17321 is a Ucn2 analog pursuing a non-GLP-1 mechanism targeting body composition through selective fat reduction while preserving muscle mass; Hanmi is completing Phase I while Genentech assumes development from Phase II onward, with preclinical data showing efficacy both as monotherapy and in combination with incretin-based treatments.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
3
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
4
How Routine Lab Markers Can Stand In for Missing Functional Status Data
5